

Form PTO-1449 (modified)	Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Donald W. KUFÉ Surender KHARBANDA	
	Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents	Foreign Patent Documents	Other Art See Page 1-2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C295	Bitko <i>et al.</i> , "Inhibition of respiratory viruses by nasally administered siRNA," <i>Nature Medicine</i> , 11:50-55, 2005.
	C296	Burncrot <i>et al.</i> , "RNAi therapeutics: a potential new class of pharmaceutical drugs," <i>Nature Chemical Biology</i> , 2:711-719, 2006.
	C297	Dykxhoorn <i>et al.</i> , "The silent treatment: siRNAs as small molecule drugs," <i>Gene Therapy</i> , 13:541-552, 2006.
	C298	Geisbert <i>et al.</i> , "Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference," <i>J. Infect. Dis.</i> , 193:1650-1657, 2006.
	C299	Grzelinski <i>et al.</i> , "RNA interference-mediated gene silencing of pleiotrophin through polythylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts," <i>Human Gene Therapy</i> , 17:751-766, 2006.
	C300	Kim <i>et al.</i> , "Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma," <i>Molecular Therapy</i> , 14:343-350, 2006.
	C301	Li <i>et al.</i> , "Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque," <i>Nature Medicine</i> , 11:944-951, 2005.
	C302	Luo <i>et al.</i> , "An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons," <i>Molecular Pain</i> , 1:29, 2005.

70675409.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents	Foreign Patent Documents	Other Art See Page 1-2	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C303	Makimura <i>et al.</i> , "Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake," <i>BMC Neuroscience</i> , 3:18, 2002.
	C304	Minakuchi <i>et al.</i> , "Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo," <i>Nucleic Acids Research</i> , 32:e109, 2004.
	C305	Nakamura <i>et al.</i> , "RNA interference targeting transforming growth factor- β type II receptor suppresses ocular inflammation and fibrosis," <i>Molecular Vision</i> , 10:703-11, 2004.
	C306	Niu <i>et al.</i> , "Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo," <i>Int. J. Gynecol. Cancer</i> , 16:743-751, 2006.
	C307	Palliser <i>et al.</i> , "An siRNA-based microbicide protects mice from lethal herpes simplex 2 infection," <i>Nature</i> , 89-94, 2006.
	C308	Reich <i>et al.</i> , "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9:210-6, 2003.
	C309	Ren <i>et al.</i> , "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents," <i>Cancer Cell</i> , 5:163-175, 2004.
	C310	Schiffelers <i>et al.</i> , "Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle," <i>Nucleic Acids Research</i> , 32:e149, 2004.
	C311	Shen <i>et al.</i> , "Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1," <i>Gene Therapy</i> , 13:225-234, 2006.
	C312	Soutschek <i>et al.</i> , "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> , 432:173-178, 2004.
	C313	Takei <i>et al.</i> , "A small interfering RNA targeting vacular endothelial growth factor as cancer therapeutics," <i>Cancer Research</i> , 64:3365-3370, 2004.
	C314	Thakker <i>et al.</i> , "siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain," <i>Molecular Psychiatry</i> , 10:782-789, 2005.
	C315	Urban-Klein <i>et al.</i> , "RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo," <i>Gene Therapy</i> , 12:461-466, 2005.
	C316	Zimmerman <i>et al.</i> , "RNAi-mediated gene silencing in non-human primates," <i>Nature</i> , 441:111-114, 2006.

70675409.1

EXAMINER: /Sean McGarry/

DATE CONSIDERED: 03/18/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/